MX337468B - Anticuerpos anti notch-1. - Google Patents

Anticuerpos anti notch-1.

Info

Publication number
MX337468B
MX337468B MX2011013717A MX2011013717A MX337468B MX 337468 B MX337468 B MX 337468B MX 2011013717 A MX2011013717 A MX 2011013717A MX 2011013717 A MX2011013717 A MX 2011013717A MX 337468 B MX337468 B MX 337468B
Authority
MX
Mexico
Prior art keywords
epitope
antibodies
notch1
nrr
domain
Prior art date
Application number
MX2011013717A
Other languages
English (en)
Spanish (es)
Other versions
MX2011013717A (es
Inventor
Zdenek Hostomsky
Kang Li
John Andrew Lippincott
Qinghai Peng
Donna Marie Stone
Ping Wei
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42575817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337468(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX2011013717A publication Critical patent/MX2011013717A/es
Publication of MX337468B publication Critical patent/MX337468B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2011013717A 2009-06-18 2010-06-16 Anticuerpos anti notch-1. MX337468B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21819309P 2009-06-18 2009-06-18
PCT/IB2010/052711 WO2010146550A1 (en) 2009-06-18 2010-06-16 Anti notch-1 antibodies

Publications (2)

Publication Number Publication Date
MX2011013717A MX2011013717A (es) 2012-05-29
MX337468B true MX337468B (es) 2016-03-02

Family

ID=42575817

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013717A MX337468B (es) 2009-06-18 2010-06-16 Anticuerpos anti notch-1.

Country Status (18)

Country Link
US (1) US9090690B2 (https=)
EP (2) EP3431501A1 (https=)
JP (2) JP6059985B2 (https=)
KR (1) KR101570898B1 (https=)
CN (1) CN102686610A (https=)
AU (1) AU2010261364B2 (https=)
BR (1) BRPI1011805A2 (https=)
CA (1) CA2765989C (https=)
CO (1) CO6480924A2 (https=)
IL (1) IL217066A0 (https=)
MX (1) MX337468B (https=)
NZ (1) NZ597611A (https=)
PE (1) PE20121494A1 (https=)
PH (1) PH12011502609B1 (https=)
RU (1) RU2011151287A (https=)
SG (1) SG176731A1 (https=)
WO (1) WO2010146550A1 (https=)
ZA (1) ZA201109282B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073717A1 (es) * 2008-10-01 2010-11-24 Genentech Inc Anticuerpos anti-notch2 de murino y humano, y metodos de uso
EP3431501A1 (en) * 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies
MX342250B (es) * 2009-09-30 2016-09-22 Genentech Inc Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
AU2011342799B2 (en) 2010-12-15 2016-06-09 Wyeth Llc Anti-Notch1 antibodies
WO2012080891A1 (en) * 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
AU2015227247A1 (en) * 2014-03-07 2016-09-15 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with Notch 1 antibodies
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
JP7525160B2 (ja) 2018-08-31 2024-07-30 Ｂｌｏｏｍ Ｔｅｃｈｎｏｌｏｇｙ 株式会社 終末糖化産物に対する抗体およびその使用
EP4585226A1 (en) 2022-09-09 2025-07-16 Institute Of Science Tokyo Therapeutic agent for coronavirus infection
CN121270710B (zh) * 2025-04-14 2026-03-31 北京光辉天成生物科技有限公司 一种高亲和力padi2抗体及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8421551D0 (en) 1984-08-24 1984-09-26 Ici Plc Water-soluble dye
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
JP2698529B2 (ja) 1993-04-06 1998-01-19 浜松ホトニクス株式会社 イメージインテンシファイア装置
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1117778A2 (en) 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2002059285A1 (en) * 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20030148954A1 (en) * 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1544210A4 (en) 2002-07-18 2006-01-25 Masayasu Okochi NEW NOTCH ORIGIN POLYPEPTIDES AND BIOMARKERS AND REAGENTS FOR WHICH THEY ARE USED
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
JP2007512348A (ja) 2003-11-26 2007-05-17 ヘルス　リサーチ　インコーポレイテッド 形質細胞の治療のためのノッチ経路干渉剤の使用
US20080220416A1 (en) 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
WO2006092062A1 (en) 2005-03-04 2006-09-08 The Hospital For Sick Children Methods for cancer prognosis
US7100777B1 (en) * 2005-07-07 2006-09-05 Jui-Chien Kao Hanger rack for hand tools
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
US20090305310A1 (en) 2005-11-22 2009-12-10 University Of Vermont And State Agricultural College Methods for Determining Notch Signaling and Uses Thereof
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US20110286916A1 (en) 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
EP3431501A1 (en) 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies
MX342250B (es) 2009-09-30 2016-09-22 Genentech Inc Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
AU2011342799B2 (en) 2010-12-15 2016-06-09 Wyeth Llc Anti-Notch1 antibodies
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies

Also Published As

Publication number Publication date
CN102686610A (zh) 2012-09-19
AU2010261364B2 (en) 2015-05-07
SG176731A1 (en) 2012-01-30
KR101570898B1 (ko) 2015-11-23
CO6480924A2 (es) 2012-07-16
NZ597611A (en) 2014-03-28
KR20120071379A (ko) 2012-07-02
MX2011013717A (es) 2012-05-29
JP2016121162A (ja) 2016-07-07
US9090690B2 (en) 2015-07-28
PH12011502609B1 (en) 2018-11-07
JP2012530487A (ja) 2012-12-06
EP2443151A1 (en) 2012-04-25
PE20121494A1 (es) 2012-11-01
JP6059985B2 (ja) 2017-01-11
EP3431501A1 (en) 2019-01-23
BRPI1011805A2 (pt) 2016-10-11
AU2010261364A1 (en) 2012-01-19
ZA201109282B (en) 2012-08-29
CA2765989A1 (en) 2010-12-23
RU2011151287A (ru) 2013-07-27
CA2765989C (en) 2016-11-29
IL217066A0 (en) 2012-02-29
US20120093813A1 (en) 2012-04-19
PH12011502609A1 (en) 2012-11-12
WO2010146550A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
PH12011502609B1 (en) Anti notch-1 antibodies
MX2024005976A (es) Un anticuerpo anti-tigit, un anticuerpo anti-pvrig y un anticuerpo anti-pd-1 para usarse en el tratamiento de cancer.
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
CR20170251A (es) Anticuerpos anti-c5 y métodos para su uso
MX2019001355A (es) Anticuerpos monoclonales multiespecíficos.
WO2013064701A3 (en) Specific antibodies and their isolation with anti-idiotypic antibodies
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
NZ608033A (en) Anti-ox40 antibodies and methods of using the same
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX2020009634A (es) Anticuerpos y metodos de uso.
EP4368704A3 (en) Cell
MX374826B (es) Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
MX2016008187A (es) Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
NZ586754A (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
EP3029069A4 (en) Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof
IL222359A0 (en) Monoclonal antibodies against her2 antigens, and uses therefor
MX347454B (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
NZ611785A (en) Anti-notch1 antibodies
NZ602115A (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2971047A4 (en) MONOCLONAL ANTIBODIES TO TRANSFERRIN AND TRANSFERRIN RECEPTOR ANTIGEN AND USES THEREOF
WO2015051320A3 (en) Anti-sox10 antibody systems and methods
WO2013115410A3 (en) Anti-phospholipase d4 antibody
WO2012149334A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies

Legal Events

Date Code Title Description
FG Grant or registration